Clinical Guideline
Trimethoprim-sulfamethoxazole

Summary
The purpose of this guideline is to guide nursing, medical and pharmacy staff in the dosing and administration of trimethoprim-sulfamethoxazole

Keywords
Trimethoprim-sulfamethoxazole, neonatal medication guideline, trimethoprim, MRSA, PJP, PCP, antibiotic, sepsis, co-trimoxazole, trimethoprim compound, UTI, urinary tract infection, sulphonamide, G6PD, kernicterus

Policy history
Is this a new policy?  N
Does this policy amend or update an existing policy?  Y v1.0
Does this policy replace an existing policy?  N
If so, which policies?

Applies to
All SA Health Portfolio
All Department for Health and Ageing Divisions
All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN, SAAS

Staff impact
All Clinical, Medical, Midwifery, Nursing, Students, Allied Health, Emergency, Mental Health, Pathology, Pharmacy

PDS reference  CG273

Version control and change history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>May 2013</td>
<td>November 2017</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>9 November 2017</td>
<td>Current</td>
<td>Complete review</td>
</tr>
</tbody>
</table>

© Department for Health and Ageing, Government of South Australia. All rights reserved.
Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms

Co-trimoxazole, trimethoprim compound.

Dose and Indications

Dose according to trimethoprim content

Infection due to susceptible organisms

Intravenous, Oral

<table>
<thead>
<tr>
<th>Postnatal Age (days)</th>
<th>Dose and Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 8 days</td>
<td>4mg/kg every 24 hours</td>
</tr>
<tr>
<td>≥ 8 days</td>
<td>4mg/kg every 12 hours</td>
</tr>
</tbody>
</table>

Prophylaxis for Pneumocystis jiroveci pneumonia (PJP) in immune deficiency

Dose according to trimethoprim content

Oral

20mg once a day on THREE days of the week (on Monday, Wednesday, Friday)
Preparation and Administration

**Intravenous**
Dilute 1mL trimethoprim 16mg-sulfamethoxazole 80mg/mL injection with 24mL Sodium Chloride 0.9% (Total volume 25mL).
The resulting solution contains 0.64mg/mL trimethoprim

<table>
<thead>
<tr>
<th>Dose</th>
<th>4mg</th>
<th>6mg</th>
<th>8mg</th>
<th>10mg</th>
<th>12mg</th>
<th>16mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>6.3mL</td>
<td>9.4mL</td>
<td>12.5mL</td>
<td>15.6mL</td>
<td>18.8mL</td>
<td>25mL</td>
</tr>
</tbody>
</table>
Start the infusion within 30 minutes of dilution. Infuse over 60 to 90 minutes.
Discard if visible turbidity or crystallisation appears in the intravenous solution during the preparation or infusion

**Intravenous – fluid restricted**
If neonate is fluid restricted dilute 1mL trimethoprim 16mg-sulfamethoxazole 80mg/mL injection with 9mL Glucose 5% (Total volume 10mL).
The resulting solution contains 1.6mg/mL trimethoprim

<table>
<thead>
<tr>
<th>Dose</th>
<th>4mg</th>
<th>6mg</th>
<th>8mg</th>
<th>10mg</th>
<th>12mg</th>
<th>16mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>2.5mL</td>
<td>3.75mL</td>
<td>5mL</td>
<td>6.25mL</td>
<td>7.5mL</td>
<td>10mL</td>
</tr>
</tbody>
</table>
Infuse over 60 minutes.
This intravenous solution is only stable for one hour as precipitation may occur in 1-2 hours.
Discard if visible turbidity or crystallisation appears in the intravenous solution during the preparation or infusion

**Oral**
Oral mixture contains trimethoprim 8mg-sulfamethoxazole 40mg/mL. Doses refer to trimethoprim component

<table>
<thead>
<tr>
<th>Dose</th>
<th>4mg</th>
<th>6mg</th>
<th>8mg</th>
<th>10mg</th>
<th>12mg</th>
<th>16mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.5mL</td>
<td>0.75mL</td>
<td>1mL</td>
<td>1.25mL</td>
<td>1.5mL</td>
<td>2mL</td>
</tr>
</tbody>
</table>
Give with feeds to minimise gastrointestinal irritation.
trimETHOPRIM-sulfamethoxazole
16mg-80mg/mL injection, 8mg-40mg/mL oral mixture

Compatible Fluids
Glucose 5%, glucose 10%, sodium chloride 0.9%, glucose/sodium chloride solutions

Adverse Effects

Common
Fever, nausea, vomiting, diarrhoea, anorexia, rash, itch, hyperkalaemia, thrombocytopenia
(rarely significant)

Infrequent
Photosensitivity, blood dyscrasias, eg neutropenia

Rare
Megaloblastic anaemia, methaemoglobinaemia, erythema, hypoglycaemia, hepatitis, crystalluria, urinary obstruction with anuria/oliguria, Clostridium difficile- associated disease, aseptic meningitis

Hypersensitivity may present with fever, cough, rash, eosinophilia; the most serious effects include anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness-like syndrome, lupus-like syndrome, pneumonitis, hepatitis, interstitial nephritis, systemic vasculitis and pancytopenia.

Monitoring
> complete blood picture and folate status during prolonged or high-dose treatment
> renal function during prolonged treatment, particularly in pre-existing renal impairment
> serum potassium (hyperkalaemia can occur but risk increases with high dose and renal impairment. Average onset is 4-5 days)

Practice Points
> Trimethoprim prescribed on its own (e.g. For urinary tract infections) is usually preferred to combined therapy with sulfamethoxazole because of the side effects associated with the sulphonamide component
> Contraindicated in glucose-6-phosphate dehydrogenase deficiency and bone marrow suppression
> Use with CAUTION in premature and newborn infants with:
  - jaundice as there is a risk of kernicterus (sulphonamides displace bilirubin from plasma albumin)
  - hepatic or renal impairment. In these circumstances it is recommended that a reduced or less frequent dosage is used
trimETHOPRIM-sulfamethoxazole
16mg-80mg/mL injection, 8mg-40mg/mL oral mixture

Version control and change history

**PDS reference:** OCE use only

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>May 2013</td>
<td>November 2017</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>9 November 2017</td>
<td>Current</td>
<td>Complete review</td>
</tr>
</tbody>
</table>